A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics
- Acronyms GRANIX
- Sponsors Teva Pharmaceutical Industries
- 26 Apr 2017 Planned End Date changed from 30 Nov 2018 to 6 Nov 2018.
- 26 Apr 2017 Planned primary completion date changed from 31 Jan 2018 to 29 Jan 2018.
- 26 Apr 2017 Status changed from not yet recruiting to recruiting.